The preliminary data open the door to an alternative approach to invasive monitoring in heart failure patients.

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

Much remains to learn about this anatomical finding, seen in about one-third of adults, and how it may affect stroke risk.

These data should help reassure those concerned with the risks of educating physicians through live cases at medical meetings ...

There remains a need to identify patients who will derive benefits from adjunctive techniques on top of pulmonary vein ...

The observed changes were favorable, but results may have been affected by better-than-normal care in the control arm.

Compared with placebo, sodium zirconium cyclosilicate was associated with less need to lower or discontinue spironolactone.

Many hope My Heart Your Heart will catalyze an effort to help patients worldwide who need but can’t afford these devices.

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?

Two studies presented at AHA show the capacity of AI to improve sonographer accuracy, consistency, and workflow.

The mixed, counterintuitive results hinder trial interpretation, but along with ARREST-AF, experts still see actionable ...